Drugs / BAY2599023
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03588299 | Nov 2018 → Sep 2026 overdue | hemophilia A | Bayer | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 2599023 | “BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene” NCT03588299 ↗ |
| Known as | DTX 201 | “BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene” NCT03588299 ↗ |
| Action | Restore | “By replacing the defective gene with a healthy copy” NCT03588299 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Adeno-associated Virus (AAV) hu37-mediated Gene Transfer” NCT03588299 ↗ |
| Route | Intravenous | “Single intravenous (IV) administration” NCT03588299 ↗ |
| Target | F8 | “human factor VIII gene” NCT03588299 ↗ |